Ipierian - About the company
Ipierian is an acquired company based in Francisco (United States), founded in 2007. It operates as a Developer of novel therapies for neurodegenerative diseases. Ipierian has raised $70.5M in funding from Google Ventures. The company has 194 active competitors, including 57 funded and 59 that have exited. Its top competitors include companies like argenx, MacroGenics and Alexion.
Company Details
Developer of novel therapies for neurodegenerative diseases. The company focused on discovering monoclonal antibodies against targets of the Tau protein. The company’s lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. iPierian has its scientific roots in the use of induced pluripotent stem cells (iPSCs) for the discovery of novel targets and therapies.
- Website
- Social
- Part Of
- bms.com
Key Metrics
Founded Year
2007
Location
Francisco, United States
Stage
Acquired
Total Funding
in 5 rounds
Latest Funding Round
Investors
Ranked
62nd among 194 active competitors
Employee Count
as on Dec 31, 2022
Similar Companies
&
Exit Details
Acquired by Bristol-Myers Squibb (Apr 29, 2014)
Legal entities associated with Ipierian
Ipierian is associated with 1 legal entity given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
Dec 31, 2006 | - | 921 | 154 |
Get your free copy of Ipierian's company profile
Ipierian's acquisition details
Ipierian got acquired by Bristol-Myers Squibb on Apr 29, 2014 at an acquisition amount of $175M.
Click to take a look at Ipierian's acquisition in detail
Ipierian's funding and investors
Ipierian has raised a total funding of $70.5M over 5 rounds. Its first funding round was on Jul 09, 2009. Its latest funding round was a Series C round on Sep 04, 2013 for $30M. 8 investors participated in its latest round, which includes Kleiner Perkins, SR One, Highland Capital Partners and ATEL Capital Group.
Ipierian has 12 institutional investors including Google Ventures, Kleiner Perkins and SR One.
Here is the list of recent funding rounds of Ipierian:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Sep 04, 2013 | $30M | Series C | 9623925 | 7148050 | SR One, , and |
Nov 08, 2010 | $29M | Series B | 9732940 | 3778524 | SR One, Mitsubishi UFJ Capital, and |
Oct 21, 2010 | $5.67M | Grant (prize money) | 2325522 | 3328854 |
Access funding benchmarks and valuations. Sign up today!View details of Ipierian's funding rounds and investors
Ipierian's Competitors and alternates
Top competitors of Ipierian include argenx, MacroGenics and Alexion. Here is the list of Top 10 competitors of Ipierian, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | Orbimed, Eiffel Investment GroupÌý&²¹³¾±è;Ìý | 73/100 | |
2nd | MacroGenics 2000, Rockville (United States), Public | Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease | $126M | InterWest Partners, Tekla Capital ManagementÌý&²¹³¾±è;Ìý | 72/100 |
3rd | Alexion 1992, Zurich (Switzerland), Acquired | Developer of therapies for patients with devastating and rare diseases | $133M | Tekla Capital Management, BB BiotechÌý&²¹³¾±è;Ìý | 70/100 |
4th | Developer of drugs for anti-cancer and anti-inflammatory diseases | $160M | Vivo Capital, Kleiner PerkinsÌý&²¹³¾±è;Ìý | 70/100 | |
5th | CytomX Therapeutics 2008, Santa Barbara (United States), Public | Developing probody therapeutics to treat cancer | $136M | Tekla Capital Management, VenrockÌý&²¹³¾±è;Ìý | 68/100 |
6th | Kodiak Sciences 2009, Palo Alto (United States), Public | Developer of therapeutics to treat retinal diseases | $35.8M | Perceptive Advisors, ArrowMark PartnersÌý&²¹³¾±è;Ìý | 67/100 |
7th | Scholar Rock 2012, Cambridge (United States), Public | Developer of Antibody-based drugs for the treatment of primary myopathies | $103M | Frazier Healthcare Partners, Polaris PartnersÌý&²¹³¾±è;Ìý | 67/100 |
8th |  BigHat 2019, San Carlos (United States), Series B | Provider of antibody therapies developed by machine learning and synthetic biology | $100M | Amgen Business Development, AME Cloud VenturesÌý&²¹³¾±è;Ìý | 67/100 |
9th |  Anthos Therapeutics 2019, Cambridge (United States), Acquired | Developer of novel anticoagulants for thrombosis treatment | $250M | Novo Holdings, BlackstoneÌý&²¹³¾±è;Ìý | 66/100 |
10th | Visterra 2007, Cambridge (United States), Acquired | Developer of monoclonal antibodies against infectious diseases | $116M | Omega Funds, Polaris PartnersÌý&²¹³¾±è;Ìý | 64/100 |
62nd | 2007, Francisco (United States), Acquired | Developer of novel therapies for neurodegenerative diseases | $70.5M | Kleiner Perkins, SR OneÌý&²¹³¾±è;Ìý | 40/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Ipierian's competitors? Click to see the top ones
Ipierian's Investments and acquisitions
Ipierian has made no investments or acquisitions yet.
Reports related to Ipierian
Here is the latest report on Ipierian's sector:
View
News related to Ipierian
•
Sofinnova Partners•Jun 19, 2019•Comet Therapeutics, Sofinnova Partners, Inkef Capital, Mission BioCapital and 13 others
•
Xconomy•Jun 15, 2011•Ipierian
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Frequently asked questions about Ipierian
When was Ipierian founded?
Ipierian was founded in 2007.Where is Ipierian located?
Ipierian is located in Francisco, United States.Is Ipierian an acquired company?
Ipierian got acquired by Bristol-Myers Squibb on Apr 29, 2014.When was the latest funding round of Ipierian?
Ipierian's latest funding round was on Sep 04, 2013.What is the annual revenue of Ipierian?
Annual revenue of Ipierian is undefined as on undefined.Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
Explore our recently published companies
- Basta - Reykjavik based, 2022 founded, Unfunded company
- Ligwood - Madison based, 2024 founded, Funding Raised company
- Plinacro - Zagreb based, 2001 founded, Funding Raised company
- Opal Therapeutics - San Francisco based, 2023 founded, Funding Raised company
- Brightwake - Nottingham based, 1979 founded, Unfunded company
- Wholesome Gift Hub - Australia based, Unfunded company
